Is glucose-6-phosphatase dehydrogenase deficiency associated with severe outcomes in hospitalized COVID-19 patients?
Abstract Glucose-6-phosphate dehydrogenase deficiency (G6PDd) is known to suppress the antioxidant system and is likely to aggravate severity of COVID-19, which results in a pro-oxidant response. This possible association has not been explored adequately in human studies. In this research, we report...
Main Authors: | Nitya Kumar, AbdulKarim AbdulRahman, Abdulla Ismaeel AlAwadhi, Manaf AlQahtani |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2021-09-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-021-98712-3 |
Similar Items
-
COVID-19 Recovery Patterns Across Alpha (B.1.1.7) and Delta (B.1.617.2) Variants of SARS-CoV-2
by: Nitya Kumar, et al.
Published: (2022-02-01) -
Quarantining arriving travelers in the era of COVID-19: balancing the risk and benefits a learning experience from Bahrain
by: Abdulkarim Abdulrahman, et al.
Published: (2021-01-01) -
Clinical and Epidemiological Characteristics of COVID-19 in a Multi-National Cohort in the Middle East
by: Saad I. Mallah, et al.
Published: (2021-03-01) -
Five novel glucose-6-phosphate dehydrogenase deficiency haplotypes correlating with disease severity
by: Dallol Ashraf, et al.
Published: (2012-09-01) -
Evaluation of Rapid Antigen Tests Using Nasal Samples to Diagnose SARS-CoV-2 in Symptomatic Patients
by: Manaf Alqahtani, et al.
Published: (2022-01-01)